Status
Conditions
Treatments
About
This is a research study to determine whether a cochlear implantation (CI) device can improve hearing in people who are deaf in one ear (known as single-sided deafness).
Full description
The goal of this study is to further investigate the role of CI in treating unilateral hearing loss and associated tinnitus. Single-sided deafness (SSD) afflicts approximately 60,000 new patients per year in the United States. The most common causes of these single-sided losses are sudden sensorineural hearing loss, Meniere's disease, trauma, and vestibular schwannoma. Patients with SSD face significant difficulty with communicating in the presence of background noise and in sound localization. Another significant problem for some SSD patients is tinnitus, which can be incapacitating and for which there are no therapies available that are considered to be of sufficient reliability to become a standard of care. Difficulty hearing in background noise and increased tinnitus can lead to significant frustration in social situations and contribute to increased isolation and a decreased quality of life. Treatment options for single sided deafness in the United States include contralateral routing of signals (CROS) hearing aids, bone-anchored hearing aids (BAHA) and use of assistive devices to improve the signal-to-noise in group situations. The first two devices take sound from the affected ear and transmit it to the unaffected ear. The last device consists of having a speaker wear a microphone and routing the signal directly to the patient's ear at a louder listening level. Although these devices can improve speech understanding in some patients, studies have shown that use of these devices does not ameliorate tinnitus or sound localization difficulties. Recent European studies have demonstrated that cochlear implantation (CI) can provide significant improvements in both perceived hearing ability and measured speech comprehension and localization in adult and pediatric patients with unilateral hearing loss. This suggests that CI may be a more effective option for this patient population than the CROS, BAHA or assistive devices.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
18 years of age or older with the ability to provide informed consent
English as the primary language
Medically and psychologically suitable
Willing to receive/have received meningitis vaccinations
Able to pay for all care received through the study, either through the subject's insurance company or through self-pay
Able to comply with study requirements, including travel to the investigational sites
Severe to profound sensorineural hearing loss (≥70 dB HL (decibel hearing level) thresholds between 500 and 4000 Hz) in the worse ear with ≤ 20% Consonant-Nucleus-Consonant (CNC) word scores
Duration of single-sided deafness ≥ one year
Tinnitus localized to the affected ear, both ears, or in the head localized to the affected ear, both ears, or in the head
Unilateral hearing loss secondary to viral or bacterial infection, such as meningitis or labyrinthitis
Ménière's disease
Sudden sensorineural hearing loss
Vascular disease affecting the inner ear
A combination of any number of the above conditions
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
11 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal